OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 How long can you feel under the weather from having Covid and flu jabs
  2. 2 What’s the chance symptoms last more than 3 days after the shot?

Answered on this page ↓

What’s the chance symptoms last more than 3 days after the shot?

Oct 7, 2026 · 5 sources used · OpenNeedle synthesis
The short version: the studies here don't give a clean probability, but most symptoms that last past 3 days are the unusual ones, and the honest answer is that nobody has measured this properly for the general population.

The one study that directly reports duration is from India: among 448 people, about 12 in 100 had symptoms lasting under a day, about 36 in 100 lasted 1–3 days, about 2 in 100 lasted 4–7 days, and under 1 in 100 lasted more than a week [3]. That puts the chance of symptoms past 3 days at roughly 3 in 100 people who got a COVID shot. But this was a single hospital-based survey in West Bengal, not a randomized trial, and it only covered Covaxin and Covishield [3].

The other studies don't give you a duration. A Sri Lankan study found symptoms in about half of people after the first dose and about 6 in 10 after the third, but never says how long they lasted [1]. A children's arthritis study said tiredness, headache, and fever resolved within 1–2 days [5]. A shoulder-pain study found most pain ended within 24 hours to 7 days, with about 7 in 100 reporting pain lasting 6–7 days after the first dose [4]. A few unusual events lasted longer: hand weakness for 13 days, chest pain averaging 6 days [2].

What's missing: no study here tracks symptoms past 3 days in a general population with modern mRNA vaccines, and none covers flu shots given alongside COVID shots. The 3 in 100 figure is a rough estimate from one survey, not a proven rate.

My call: expect roughly 3 in 100 people to still feel symptoms past day 3 after a COVID shot, but the evidence is too thin to call it a firm probability. Confidence: low.

Keep digging

Sources used 5

  1. Prevalence, severity and duration of post-vaccination symptoms following COVID-19 vaccination in a working-aged population in Galle district, Sri Lanka Ceylon Journal of Science (2025) Thin

    Post-vaccination symptoms are common among working-age adults in Galle District, Sri Lanka, peaking after the third COVID-19 vaccine dose and showing vaccine- and demographic-specific patterns.

    DOI: 10.4038/cjs.v54i1.8343
  2. Safety of COVID‐19 vaccines Journal of Medical Virology (2021) Thin

    A cross-sectional survey of 1,736 adults in Iraq and Jordan assessed post-vaccination adverse effects after Pfizer-BioNTech, AstraZeneca, and Sinopharm vaccines, finding generally mild to moderate reactogenicity with Sinopharm showing comparatively fewer adverse effects and seve…

    DOI: 10.1002/jmv.27214
  3. Motivational Factors and Post Vaccination Symptoms among COVID-19 Vaccinated Beneficiaries at a Tertiary Care Hospital, West Bengal, India: A Cross-sectional Study JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH (2022) Thin

    Cross-sectional survey of 448 COVID-19 vaccine recipients at a West Bengal tertiary care hospital finds about half experienced post-vaccination symptoms (mostly mild local pain), with fear of infection and self-motivation the main vaccination drivers and universal acceptance obs…

    DOI: 10.7860/jcdr/2022/57598.17027
  4. Association of Post Vaccination Shoulder Pain with Sinovac and Astrazeneca COVID-19 Vaccines: A Cross-Sectional Study Pakistan BioMedical Journal (2022) primary study Strong

    A cross-sectional study of 143 adults in Lahore found a statistically significant association between shoulder pain and receipt of Sinovac or AstraZeneca COVID-19 vaccines, with 65% reporting pain after the first dose and 50.3% after the second (Chi-square p<0.001).

    DOI: 10.54393/pbmj.v5i7.597
  5. Safety of the BNT162b2 mRNA COVID-19 vaccine in children and adolescents with juvenile idiopathic arthritis: a tertiary-center early experience Egyptian Rheumatology and Rehabilitation (2022) Thin

    A prospective cohort study of 36 children and adolescents with juvenile idiopathic arthritis found that the BNT162b2 mRNA COVID-19 vaccine was safe, producing mostly mild and transient local and systemic adverse events with no serious events and no disease flares.

    DOI: 10.1186/s43166-022-00143-z

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →